CN1596122A - 包括因子VII多肽和PAl－1多肽的药物组合物 - Google Patents
包括因子VII多肽和PAl－1多肽的药物组合物 Download PDFInfo
- Publication number
- CN1596122A CN1596122A CNA028236777A CN02823677A CN1596122A CN 1596122 A CN1596122 A CN 1596122A CN A028236777 A CNA028236777 A CN A028236777A CN 02823677 A CN02823677 A CN 02823677A CN 1596122 A CN1596122 A CN 1596122A
- Authority
- CN
- China
- Prior art keywords
- pai
- factor vii
- polypeptide
- factor
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940012413 factor vii Drugs 0.000 title claims abstract description 382
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 354
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 354
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 354
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 20
- 102100023804 Coagulation factor VII Human genes 0.000 claims abstract description 383
- 108010023321 Factor VII Proteins 0.000 claims abstract description 382
- 208000032843 Hemorrhage Diseases 0.000 claims abstract description 130
- 239000000203 mixture Substances 0.000 claims abstract description 64
- 208000034158 bleeding Diseases 0.000 claims abstract description 38
- 230000000740 bleeding effect Effects 0.000 claims abstract description 38
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 claims abstract 64
- 238000002360 preparation method Methods 0.000 claims description 120
- 238000012360 testing method Methods 0.000 claims description 105
- 238000000034 method Methods 0.000 claims description 96
- 108010054265 Factor VIIa Proteins 0.000 claims description 75
- 229940012414 factor viia Drugs 0.000 claims description 75
- 230000000694 effects Effects 0.000 claims description 72
- 239000002552 dosage form Substances 0.000 claims description 59
- 230000023597 hemostasis Effects 0.000 claims description 37
- 238000011282 treatment Methods 0.000 claims description 32
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 26
- 239000003814 drug Substances 0.000 claims description 26
- 238000002560 therapeutic procedure Methods 0.000 claims description 22
- 229940099816 human factor vii Drugs 0.000 claims description 20
- 230000004913 activation Effects 0.000 claims description 19
- 230000002439 hemostatic effect Effects 0.000 claims description 10
- 101000609255 Homo sapiens Plasminogen activator inhibitor 1 Proteins 0.000 claims description 8
- 102000043283 human SERPINE1 Human genes 0.000 claims description 8
- 230000007062 hydrolysis Effects 0.000 claims description 8
- 238000006460 hydrolysis reaction Methods 0.000 claims description 8
- 238000001802 infusion Methods 0.000 claims description 7
- 239000004615 ingredient Substances 0.000 claims description 7
- 238000002347 injection Methods 0.000 claims description 7
- 239000007924 injection Substances 0.000 claims description 7
- 230000008521 reorganization Effects 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 2
- 102000012335 Plasminogen Activator Inhibitor 1 Human genes 0.000 claims 62
- 102100039418 Plasminogen activator inhibitor 1 Human genes 0.000 abstract 2
- 102000010752 Plasminogen Inactivators Human genes 0.000 description 348
- 108010077971 Plasminogen Inactivators Proteins 0.000 description 348
- 239000002797 plasminogen activator inhibitor Substances 0.000 description 330
- 108090000190 Thrombin Proteins 0.000 description 62
- 210000001772 blood platelet Anatomy 0.000 description 62
- 229960004072 thrombin Drugs 0.000 description 62
- 210000004369 blood Anatomy 0.000 description 43
- 239000008280 blood Substances 0.000 description 43
- 210000002381 plasma Anatomy 0.000 description 39
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 32
- 102000009123 Fibrin Human genes 0.000 description 31
- 108010073385 Fibrin Proteins 0.000 description 31
- 229950003499 fibrin Drugs 0.000 description 31
- 208000027418 Wounds and injury Diseases 0.000 description 25
- 210000004027 cell Anatomy 0.000 description 24
- 108010000499 Thromboplastin Proteins 0.000 description 22
- 102000002262 Thromboplastin Human genes 0.000 description 22
- 229940024606 amino acid Drugs 0.000 description 22
- 235000001014 amino acid Nutrition 0.000 description 21
- 230000008859 change Effects 0.000 description 21
- 206010052428 Wound Diseases 0.000 description 20
- 150000001413 amino acids Chemical class 0.000 description 19
- 230000023555 blood coagulation Effects 0.000 description 19
- 208000011580 syndromic disease Diseases 0.000 description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 16
- 230000006378 damage Effects 0.000 description 15
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 14
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 14
- 239000003146 anticoagulant agent Substances 0.000 description 13
- 201000010099 disease Diseases 0.000 description 13
- 230000020764 fibrinolysis Effects 0.000 description 13
- 230000006870 function Effects 0.000 description 13
- 230000008569 process Effects 0.000 description 13
- 235000018102 proteins Nutrition 0.000 description 13
- 102000004169 proteins and genes Human genes 0.000 description 13
- 108010013773 recombinant FVIIa Proteins 0.000 description 13
- 108010076282 Factor IX Proteins 0.000 description 12
- 230000000975 bioactive effect Effects 0.000 description 12
- 208000015294 blood coagulation disease Diseases 0.000 description 12
- 239000003112 inhibitor Substances 0.000 description 12
- 206010053567 Coagulopathies Diseases 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
- 230000002950 deficient Effects 0.000 description 11
- 108010014173 Factor X Proteins 0.000 description 10
- 108010049003 Fibrinogen Proteins 0.000 description 10
- 102000008946 Fibrinogen Human genes 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 10
- 229960004222 factor ix Drugs 0.000 description 10
- 229940012952 fibrinogen Drugs 0.000 description 10
- 230000017854 proteolysis Effects 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- 102100022641 Coagulation factor IX Human genes 0.000 description 9
- 229940030225 antihemorrhagics Drugs 0.000 description 9
- 230000015271 coagulation Effects 0.000 description 9
- 238000005345 coagulation Methods 0.000 description 9
- 230000000025 haemostatic effect Effects 0.000 description 9
- 210000000056 organ Anatomy 0.000 description 9
- 238000000746 purification Methods 0.000 description 9
- 230000002829 reductive effect Effects 0.000 description 9
- 235000002639 sodium chloride Nutrition 0.000 description 9
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 8
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 8
- 229940127219 anticoagulant drug Drugs 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- 206010043554 thrombocytopenia Diseases 0.000 description 8
- 229960000187 tissue plasminogen activator Drugs 0.000 description 8
- 108010074860 Factor Xa Proteins 0.000 description 7
- 238000007385 chemical modification Methods 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 239000013068 control sample Substances 0.000 description 7
- 238000010790 dilution Methods 0.000 description 7
- 239000012895 dilution Substances 0.000 description 7
- 208000014674 injury Diseases 0.000 description 7
- 230000002265 prevention Effects 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 102000010911 Enzyme Precursors Human genes 0.000 description 6
- 108010062466 Enzyme Precursors Proteins 0.000 description 6
- 208000031220 Hemophilia Diseases 0.000 description 6
- 208000009292 Hemophilia A Diseases 0.000 description 6
- 102000035195 Peptidases Human genes 0.000 description 6
- 108091005804 Peptidases Proteins 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 6
- 238000001042 affinity chromatography Methods 0.000 description 6
- 230000004071 biological effect Effects 0.000 description 6
- 239000003114 blood coagulation factor Substances 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 208000031169 hemorrhagic disease Diseases 0.000 description 6
- 230000002962 histologic effect Effects 0.000 description 6
- 238000001990 intravenous administration Methods 0.000 description 6
- 230000003902 lesion Effects 0.000 description 6
- 230000000670 limiting effect Effects 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 208000013607 Glanzmann thrombasthenia Diseases 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 5
- 241000282898 Sus scrofa Species 0.000 description 5
- 230000007812 deficiency Effects 0.000 description 5
- 230000008034 disappearance Effects 0.000 description 5
- 239000003527 fibrinolytic agent Substances 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 238000011835 investigation Methods 0.000 description 5
- 238000004255 ion exchange chromatography Methods 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 238000002703 mutagenesis Methods 0.000 description 5
- 231100000350 mutagenesis Toxicity 0.000 description 5
- 229940112216 novoseven Drugs 0.000 description 5
- 238000005215 recombination Methods 0.000 description 5
- 230000006798 recombination Effects 0.000 description 5
- 230000006641 stabilisation Effects 0.000 description 5
- 230000002537 thrombolytic effect Effects 0.000 description 5
- 108090000201 Carboxypeptidase B2 Proteins 0.000 description 4
- 102100035023 Carboxypeptidase B2 Human genes 0.000 description 4
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 241000009328 Perro Species 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 208000027276 Von Willebrand disease Diseases 0.000 description 4
- 230000002421 anti-septic effect Effects 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 238000005336 cracking Methods 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- 230000003480 fibrinolytic effect Effects 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 230000036470 plasma concentration Effects 0.000 description 4
- 238000001742 protein purification Methods 0.000 description 4
- 208000012137 von Willebrand disease (hereditary or acquired) Diseases 0.000 description 4
- 229960001134 von willebrand factor Drugs 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 102100026735 Coagulation factor VIII Human genes 0.000 description 3
- 206010010356 Congenital anomaly Diseases 0.000 description 3
- 108010054218 Factor VIII Proteins 0.000 description 3
- 102000001690 Factor VIII Human genes 0.000 description 3
- 108010074864 Factor XI Proteins 0.000 description 3
- 108010088842 Fibrinolysin Proteins 0.000 description 3
- 206010017866 Gastritis haemorrhagic Diseases 0.000 description 3
- 208000034486 Multi-organ failure Diseases 0.000 description 3
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 102100031358 Urokinase-type plasminogen activator Human genes 0.000 description 3
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 239000000853 adhesive Substances 0.000 description 3
- 230000001070 adhesive effect Effects 0.000 description 3
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 239000003130 blood coagulation factor inhibitor Substances 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 230000003197 catalytic effect Effects 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 239000006143 cell culture medium Substances 0.000 description 3
- 239000003593 chromogenic compound Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000000701 coagulant Substances 0.000 description 3
- 238000004891 communication Methods 0.000 description 3
- 239000003599 detergent Substances 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 238000007922 dissolution test Methods 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 210000003725 endotheliocyte Anatomy 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 230000002349 favourable effect Effects 0.000 description 3
- 229940001501 fibrinolysin Drugs 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 3
- 150000003904 phospholipids Chemical class 0.000 description 3
- 238000010188 recombinant method Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 238000001542 size-exclusion chromatography Methods 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 238000011476 stem cell transplantation Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- 241000972773 Aulopiformes Species 0.000 description 2
- 101100232929 Caenorhabditis elegans pat-4 gene Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 241000283073 Equus caballus Species 0.000 description 2
- 201000003542 Factor VIII deficiency Diseases 0.000 description 2
- 101710145505 Fiber protein Proteins 0.000 description 2
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 206010018852 Haematoma Diseases 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 238000012752 Hepatectomy Methods 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 108010090444 Innovin Proteins 0.000 description 2
- 208000008574 Intracranial Hemorrhages Diseases 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 108010094028 Prothrombin Proteins 0.000 description 2
- 102100027378 Prothrombin Human genes 0.000 description 2
- 241000125945 Protoparvovirus Species 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 239000008365 aqueous carrier Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 239000010836 blood and blood product Substances 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 229940125691 blood product Drugs 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 238000007599 discharging Methods 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 201000007386 factor VII deficiency Diseases 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000007849 functional defect Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 208000002085 hemarthrosis Diseases 0.000 description 2
- 208000006750 hematuria Diseases 0.000 description 2
- 208000009429 hemophilia B Diseases 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 238000002357 laparoscopic surgery Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 230000004199 lung function Effects 0.000 description 2
- 239000008176 lyophilized powder Substances 0.000 description 2
- 230000002101 lytic effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000005497 microtitration Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 210000004303 peritoneum Anatomy 0.000 description 2
- 210000003800 pharynx Anatomy 0.000 description 2
- 230000010118 platelet activation Effects 0.000 description 2
- 230000004481 post-translational protein modification Effects 0.000 description 2
- 235000019353 potassium silicate Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000013615 primer Substances 0.000 description 2
- 239000003805 procoagulant Substances 0.000 description 2
- 229940039716 prothrombin Drugs 0.000 description 2
- 235000019515 salmon Nutrition 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- NTHWMYGWWRZVTN-UHFFFAOYSA-N sodium silicate Chemical class [Na+].[Na+].[O-][Si]([O-])=O NTHWMYGWWRZVTN-UHFFFAOYSA-N 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 102000004092 Amidohydrolases Human genes 0.000 description 1
- 108090000531 Amidohydrolases Proteins 0.000 description 1
- 101100046775 Arabidopsis thaliana TPPA gene Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 206010003658 Atrial Fibrillation Diseases 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 101100518972 Caenorhabditis elegans pat-6 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 206010053942 Cerebral haematoma Diseases 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 102100030563 Coagulation factor XI Human genes 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 206010052806 Drug tolerance increased Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 206010015866 Extravasation Diseases 0.000 description 1
- 108010000196 Factor XIIIa Proteins 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 102000001399 Kallikrein Human genes 0.000 description 1
- 108060005987 Kallikrein Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000010718 Multiple Organ Failure Diseases 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 108010035030 Platelet Membrane Glycoprotein IIb Proteins 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 101800004937 Protein C Proteins 0.000 description 1
- 102000017975 Protein C Human genes 0.000 description 1
- 101800001700 Saposin-D Proteins 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 238000012867 alanine scanning Methods 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 230000003024 amidolytic effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- -1 antiseptic Substances 0.000 description 1
- 239000003698 antivitamin K Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000037058 blood plasma level Effects 0.000 description 1
- 208000014759 blood platelet disease Diseases 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000000080 chela (arthropods) Anatomy 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 230000009852 coagulant defect Effects 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000037011 constitutive activity Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000011262 co‐therapy Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000002050 diffraction method Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000036251 extravasation Effects 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 239000012847 fine chemical Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 210000003677 hemocyte Anatomy 0.000 description 1
- 229940000351 hemocyte Drugs 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 102000057593 human F8 Human genes 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000001035 methylating effect Effects 0.000 description 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 238000005222 photoaffinity labeling Methods 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 229960000856 protein c Drugs 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 210000003689 pubic bone Anatomy 0.000 description 1
- 208000005333 pulmonary edema Diseases 0.000 description 1
- 238000011473 radical retropubic prostatectomy Methods 0.000 description 1
- 229940047431 recombinate Drugs 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008085 renal dysfunction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000003582 thrombocytopenic effect Effects 0.000 description 1
- 230000009424 thromboembolic effect Effects 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- XZZNDPSIHUTMOC-UHFFFAOYSA-N triphenyl phosphate Chemical compound C=1C=CC=CC=1OP(OC=1C=CC=CC=1)(=O)OC1=CC=CC=C1 XZZNDPSIHUTMOC-UHFFFAOYSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000001810 trypsinlike Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 210000002438 upper gastrointestinal tract Anatomy 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 244000052613 viral pathogen Species 0.000 description 1
- 229940019333 vitamin k antagonists Drugs 0.000 description 1
- 229960005080 warfarin Drugs 0.000 description 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Surgery (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200101671 | 2001-11-09 | ||
| DKPA200101671 | 2001-11-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1596122A true CN1596122A (zh) | 2005-03-16 |
Family
ID=8160829
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA028236777A Pending CN1596122A (zh) | 2001-11-09 | 2002-11-05 | 包括因子VII多肽和PAl－1多肽的药物组合物 |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP1446146A1 (ja) |
| JP (1) | JP2005510514A (ja) |
| KR (1) | KR20050043733A (ja) |
| CN (1) | CN1596122A (ja) |
| AU (1) | AU2002340778B2 (ja) |
| BR (1) | BR0213952A (ja) |
| CA (1) | CA2464614A1 (ja) |
| CZ (1) | CZ2004535A3 (ja) |
| HU (1) | HUP0401959A3 (ja) |
| IL (1) | IL161523A0 (ja) |
| NO (1) | NO20042379L (ja) |
| PL (1) | PL370118A1 (ja) |
| RU (1) | RU2304980C2 (ja) |
| WO (1) | WO2003039580A1 (ja) |
| ZA (1) | ZA200403270B (ja) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111205244A (zh) * | 2018-11-22 | 2020-05-29 | 上海科技大学 | 噻唑并环类化合物、其制备方法、中间体和应用 |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009045412A2 (en) * | 2007-10-01 | 2009-04-09 | American Diagnostica, Inc. | Methods of treatment using modified plasminogen activator inhibitor type-1 molecules |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998058661A1 (en) * | 1997-06-23 | 1998-12-30 | Novo Nordisk A/S | Use of fviia for the treatment of bleedings in patients with a normal blood clotting cascade and normal platelet function |
| AT409335B (de) * | 1998-11-10 | 2002-07-25 | Immuno Ag | Pharmazeutisches präparat enthaltend einen rezeptor-antagonisten zur behandlung von blutgerinnungsstörungen |
| ATE485371T1 (de) * | 2000-05-03 | 2010-11-15 | Novo Nordisk Healthcare Ag | Varianten des menschlichen koagulationsfaktors vii |
-
2002
- 2002-11-05 PL PL02370118A patent/PL370118A1/xx not_active Application Discontinuation
- 2002-11-05 WO PCT/DK2002/000735 patent/WO2003039580A1/en active IP Right Grant
- 2002-11-05 EP EP02774474A patent/EP1446146A1/en not_active Withdrawn
- 2002-11-05 CN CNA028236777A patent/CN1596122A/zh active Pending
- 2002-11-05 CA CA002464614A patent/CA2464614A1/en not_active Abandoned
- 2002-11-05 AU AU2002340778A patent/AU2002340778B2/en not_active Ceased
- 2002-11-05 KR KR1020047006606A patent/KR20050043733A/ko not_active Application Discontinuation
- 2002-11-05 JP JP2003541871A patent/JP2005510514A/ja not_active Withdrawn
- 2002-11-05 CZ CZ2004535A patent/CZ2004535A3/cs unknown
- 2002-11-05 IL IL16152302A patent/IL161523A0/xx unknown
- 2002-11-05 HU HU0401959A patent/HUP0401959A3/hu unknown
- 2002-11-05 RU RU2004117535/15A patent/RU2304980C2/ru not_active IP Right Cessation
- 2002-11-05 BR BR0213952-9A patent/BR0213952A/pt not_active IP Right Cessation
-
2004
- 2004-04-30 ZA ZA200403270A patent/ZA200403270B/en unknown
- 2004-06-08 NO NO20042379A patent/NO20042379L/no unknown
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111205244A (zh) * | 2018-11-22 | 2020-05-29 | 上海科技大学 | 噻唑并环类化合物、其制备方法、中间体和应用 |
| CN111205244B (zh) * | 2018-11-22 | 2023-08-18 | 上海科技大学 | 噻唑并环类化合物、其制备方法、中间体和应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2464614A1 (en) | 2003-05-15 |
| PL370118A1 (en) | 2005-05-16 |
| RU2304980C2 (ru) | 2007-08-27 |
| ZA200403270B (en) | 2004-11-08 |
| AU2002340778B2 (en) | 2007-08-02 |
| CZ2004535A3 (cs) | 2005-01-12 |
| HUP0401959A2 (hu) | 2004-12-28 |
| KR20050043733A (ko) | 2005-05-11 |
| RU2004117535A (ru) | 2005-04-10 |
| NO20042379L (no) | 2004-06-08 |
| HUP0401959A3 (en) | 2009-03-30 |
| BR0213952A (pt) | 2004-08-31 |
| WO2003039580A1 (en) | 2003-05-15 |
| JP2005510514A (ja) | 2005-04-21 |
| EP1446146A1 (en) | 2004-08-18 |
| IL161523A0 (en) | 2004-09-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1304049C (zh) | 包含因子VIIα和因子XIII的药物组合物 | |
| CN1499981A (zh) | Vii因子多肽和ix因子多肽的联合应用 | |
| US7078479B2 (en) | Pharmaceutical composition comprising factor VII polypeptides and alpha2-antiplasmin polypeptides | |
| US20080069810A1 (en) | Pharmaceutical Composition Comprising Factor VII Polypeptides and TAFI Polypeptides | |
| US20110059894A1 (en) | Factor VII Polypeptides for Preventing Formation of Inhibitors in Subjects with Haemophilia | |
| EP1446150A1 (en) | Pharmaceutical composition comprising factor vii polypeptides and protein c inhibitors | |
| CN1304050C (zh) | 含有因子ⅶ多肽和因子ⅺ多肽的药用组合物 | |
| US20030119743A1 (en) | Pharmaceutical composition comprising factor VII polypeptides and tissue plasminogen inhibitors | |
| US20070219135A1 (en) | Pharmaceutical Composition Comprising Factor VII Polypeptides and PAI-1 Polypeptide | |
| AU2002354846A1 (en) | Pharmaceutical composition comprising factor VII polypeptides and factor XI polypeptides | |
| US20030119741A1 (en) | Pharmaceutical composition comprising factor VII polypeptides and aprotinin polypeptides | |
| US20080075709A1 (en) | Pharmaceutical Composition Comprising Factor VII Polypeptides And Thrombomodulin Polypeptides | |
| CN1596125A (zh) | 包括因子ⅶ多肽和因子ⅴ多肽的药物组合物 | |
| CN1596122A (zh) | 包括因子VII多肽和PAl－1多肽的药物组合物 | |
| AU2002340779A1 (en) | Pharmaceutical composition comprising factor VII polypeptides and factor V polypeptides | |
| EP1446155A1 (en) | Pharmaceutical composition comprising factor vii polypeptides and aprotinin polypeptides | |
| EP1446145A1 (en) | Pharmaceutical composition comprising factor vii polypeptides and tafi polypeptides | |
| AU2002340778A1 (en) | Pharmaceutical composition comprising factor VII polypeptides and PAI-1 polypeptides | |
| WO2003039588A1 (en) | Pharmaceutical composition comprising factor vii polypeptides and tissue plasminogen inhibitors | |
| WO2003039587A1 (en) | Pharmaceutical composition comprising factor vii polypeptides and protein s inhibitors | |
| US20080057059A1 (en) | Pharmaceutical Composition Comprising Factor VII Polypeptides and Protein S Inhibitors | |
| WO2003039589A1 (en) | Pharmaceutical composition comprising factor vii polypeptides and alpha2 -antiplasmin polypeptides | |
| EP1446151A1 (en) | Pharmaceutical composition comprising factor vii polypeptides and thrombomodulin polypeptides |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |